JP2013529181A5 - - Google Patents

Download PDF

Info

Publication number
JP2013529181A5
JP2013529181A5 JP2013501487A JP2013501487A JP2013529181A5 JP 2013529181 A5 JP2013529181 A5 JP 2013529181A5 JP 2013501487 A JP2013501487 A JP 2013501487A JP 2013501487 A JP2013501487 A JP 2013501487A JP 2013529181 A5 JP2013529181 A5 JP 2013529181A5
Authority
JP
Japan
Prior art keywords
pkd1
antibody
human mammal
mammal
endogenous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013501487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013529181A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/029806 external-priority patent/WO2011119842A1/en
Publication of JP2013529181A publication Critical patent/JP2013529181A/ja
Publication of JP2013529181A5 publication Critical patent/JP2013529181A5/ja
Pending legal-status Critical Current

Links

JP2013501487A 2010-03-25 2011-03-24 神経障害を治療するための組成物および方法 Pending JP2013529181A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31759810P 2010-03-25 2010-03-25
US61/317,598 2010-03-25
PCT/US2011/029806 WO2011119842A1 (en) 2010-03-25 2011-03-24 Compositions and methods for treating neurological disorders

Publications (2)

Publication Number Publication Date
JP2013529181A JP2013529181A (ja) 2013-07-18
JP2013529181A5 true JP2013529181A5 (https=) 2014-05-08

Family

ID=44673620

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013501487A Pending JP2013529181A (ja) 2010-03-25 2011-03-24 神経障害を治療するための組成物および方法

Country Status (4)

Country Link
US (2) US9359445B2 (https=)
EP (1) EP2550361B1 (https=)
JP (1) JP2013529181A (https=)
WO (1) WO2011119842A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2761587T3 (es) * 2013-08-07 2020-05-20 Friedrich Miescher Institute For Biomedical Res Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
AU2015327836B2 (en) 2014-10-03 2021-07-01 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
CN108603230A (zh) 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
CA3053245A1 (en) * 2017-02-09 2018-08-16 Cognoa, Inc. Platform and system for digital personalized medicine
US11436719B2 (en) 2017-02-16 2022-09-06 Kyoto University Cell evaluation method, cell evaluation device, and recording medium storing cell evaluation program
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR102318434B1 (ko) 2017-08-25 2021-11-01 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
CA3099280A1 (en) 2018-05-04 2019-11-07 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
AU2020227825B2 (en) 2019-02-27 2026-03-26 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases
CN115867657A (zh) 2020-05-11 2023-03-28 斯托克制药公司 用于治疗疾患和疾病的opa1反义寡聚物
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
CN116739148A (zh) * 2023-05-17 2023-09-12 北京海卓飞网络科技有限公司 面向社交网络的用户关系分析方法、装置、设备及介质

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2061416T3 (es) 1990-10-12 1997-03-01 Max Planck Gesellschaft Ribozimas modificadas.
DE4216134A1 (de) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
DE69333930T8 (de) 1993-01-22 2007-02-22 The Regents Of The University Of Colorado, Boulder Lokalisierung von therapeutischen mitteln
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5716824A (en) 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
US7964598B2 (en) 1995-10-17 2011-06-21 The J. David Gladstone Institutes ApoE4 domain interaction inhibitors and methods of use thereof
WO1997026270A2 (en) 1996-01-16 1997-07-24 Ribozyme Pharmaceuticals, Inc. Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
DE19650758C1 (de) * 1996-12-06 1998-01-02 Deutsches Krebsforsch PKD1-Fragmente mit Bindungsregionen für PKD1-spezifische Antikörper
US6124272A (en) * 1999-04-09 2000-09-26 Isis Pharmaceutical Inc. Antisense modulation of PDK-1 expression
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20050233329A1 (en) 2002-02-20 2005-10-20 Sirna Therapeutics, Inc. Inhibition of gene expression using duplex forming oligonucleotides
US20050282188A1 (en) 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
AU2004266311B2 (en) 2001-05-18 2009-07-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
IL160701A0 (en) 2001-09-21 2004-08-31 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
US20060004043A1 (en) 2003-11-19 2006-01-05 Bhagwat Shripad S Indazole compounds and methods of use thereof
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
GB0602178D0 (en) * 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
JP2009534458A (ja) 2006-04-26 2009-09-24 キャンサー・リサーチ・テクノロジー・リミテッド アミノ−エチル−アミノ−アリール(aeaa)化合物およびそれらの使用
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
US8240498B2 (en) 2006-10-31 2012-08-14 Crown Packaging Technology, Inc. Resealable closure
US8618063B2 (en) * 2008-04-09 2013-12-31 The Board Of Trustees Of The University Of Illinois Method for treating a synucleinopathy
EP2297311A1 (en) * 2008-06-06 2011-03-23 Medizinische Universität Graz Compounds reducing or inhibiting the expression of pkd1 for diagnosis and therapy of brain tumors
ES2385276B1 (es) 2010-02-25 2013-07-05 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer.

Similar Documents

Publication Publication Date Title
JP2013529181A5 (https=)
Carty et al. Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of huntington s disease: an in vivo High-Content imaging study
Kulkarni‐Gosavi et al. Form and function of the Golgi apparatus: scaffolds, cytoskeleton and signalling
Park et al. MTERF3 is a negative regulator of mammalian mtDNA transcription
Ulusoy et al. Caudo‐rostral brain spreading of α‐synuclein through vagal connections
Zaharieva et al. Concentration and localization of coexpressed ELAV/Hu proteins control specificity of mRNA processing
Sobajima et al. Rab11a is required for apical protein localisation in the intestine
Nagara et al. Impaired Cytoplasmic–Nuclear Transport of Hypoxia‐Inducible Factor‐1α in Amyotrophic Lateral Sclerosis
HRP20231707T1 (hr) Životinje koje nisu ljudi, koje sadrže humanizirani gen iz diferencijacijske skupine 47
JP2011501652A5 (https=)
Razafsky et al. LINC complexes mediate the positioning of cone photoreceptor nuclei in mouse retina
Tulgren et al. The Nesprin family member ANC-1 regulates synapse formation and axon termination by functioning in a pathway with RPM-1 and β-Catenin
Tivodar et al. Rac-GTPases regulate microtubule stability and axon growth of cortical GABAergic interneurons
Navarro et al. The nucleus is a conserved mechanosensation and mechanoresponse organelle
Pelletier et al. An early onset progressive motor neuron disorder in Scyl1-deficient mice is associated with mislocalization of TDP-43
Huang et al. Profiling the genes affected by pathogenic TDP‐43 in astrocytes
HRP20202034T1 (hr) Neljudske životinje s genom za humanizirani diferencijacijski biljeg cd274
JP2016527891A5 (https=)
JP2009525046A5 (https=)
Wang et al. Sun1 deficiency leads to cerebellar ataxia in mice
Abrakhi et al. Nanoscale analysis reveals the maturation of neurodegeneration-associated protein aggregates: grown in mRNA granules then released by stress granule proteins
Wang et al. Synapsin-promoted caveolin-1 overexpression maintains mitochondrial morphology and function in PSAPP Alzheimer’s disease mice
Tomioka et al. Ependymal cells of the mouse brain express urate transporter 1 (URAT1)
Tomioka et al. Immunohistochemical and in situ hybridization study of urate transporters GLUT9/URATv1, ABCG2, and URAT1 in the murine brain
WO2013052814A3 (en) E1 enzyme mutants and uses thereof